Abstract
Do geometric features of hepatocellular carcinomas correlate with survival following radiofrequency ablation (RFA) with and without lyso-thermosensitive liposomal doxorubicin (LTLD/Thermodox)? M. Castro, S. Leonard, H. Celik, P. Wakim, J. Karanian, W. Pritchard, N. Borys, R. Lencioni, M. O’Neal, W. Tak, B. Wood; NIH, Bethesda, MD; FDA/CDRH Laboratory of Cardiovascular and Interventional Therapeutics, Laurel, MD; Food and Drug Administration, Rockville, MD; Celsion Corporation, Princeton, NJ; University of Miami Miller School of Medicine, Miami, FL; BioClinica,Inc., Princeton, NJ; Kyungpook National University Hospital, Jung-gu, Daegu.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
